SMARCC2 combined with c‑Myc inhibits the migration and invasion of glioma cells via modulation of the Wnt/β‑catenin signaling pathway

Li,Chiyang; Fei,Chengshuo; Li,Junjie; Wu,Hang; Chen,Lei; Roshani,Ramzi; Li,Hong; Shi,Linyong; Song,Chong; Gu,Junwei; Lu,Yuntao; Zhou,Qiang

doi:10.3892/mmr.2021.12190

SMARCC2 combined with c‑Myc inhibits the migration and invasion of glioma cells via modulation of the Wnt/β‑catenin signaling pathway

Authors:
- Chiyang Li
- Chengshuo Fei
- Junjie Li
- Hang Wu
- Lei Chen
- Ramzi Roshani
- Hong Li
- Linyong Shi
- Chong Song
- Junwei Gu
- Yuntao Lu
- Qiang Zhou
View Affiliations

Affiliations: Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
Published online on: June 2, 2021 https://doi.org/10.3892/mmr.2021.12190
Article Number: 551
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioma is the most common type of central nervous system tumor. SWItch/sucrose non‑fermentable (SWI/SNF) is a tumor suppressor that serves an important role in epithelial‑mesenchymal transition (EMT). The present study aimed to identify key molecules involved in the EMT process. SWI/SNF related, matrix associated, actin dependent regulator of chromatin subfamily c member 2 (SMARCC2) is mutated in and its expression is low in multiple types of cancer. SMARCC2 is the core subunit of the chromatin‑remodeling complex, SWI/SNF. Relative mRNA SMARCC2 expression levels in human glioma tissue were analyzed via reverse transcription‑quantitative PCR, whereas the protein expression levels were determined via immunohistochemistry staining. SMARCC2 expression was knocked down in glioma cells using small interfering RNA (si) and overexpressed by infection with adenovirus vectors carrying SMARCC2 cDNA. Wound healing and Transwell assays were performed to assess cell migration and invasion, respectively. Subsequently, immunofluorescence and western blotting were performed to analyze the expression levels of the oncogene c‑Myc, which is associated with SMARCC2. SMARCC2 combines with C‑MYC to downregulate its expression. Consistent with the results of the bioinformatics analysis, which revealed that the upregulated expression levels of SMARCC2 were associated with a more favorable prognosis in patients with glioma, the mRNA and protein expression levels of SMARCC2 were significantly upregulated in low‑grade glioma tissues compared with high‑grade glioma tissues. The results of the wound healing assay demonstrated that cell migration was significantly increased in the siSMARCC2‑1/3 groups compared with the negative control (NC) group. By contrast, the migratory ability of cells was significantly reduced following transduction with adenovirus overexpressing SMARCC2, which upregulated the expression of SMARCC2, compared with the lentiviral vector‑non‑specific control (LVS‑NC) group. The Transwell assay results further showed that SMARCC2 overexpression significantly inhibited the migratory and invasive abilities of U87MG and LN229 cells compared with the LVS‑NC group. Co‑immunoprecipitation assays were subsequently conducted to validate the binding of SMARCC2 and c‑Myc; the results demonstrated that the expression of c‑Myc was downregulated in adenovirus‑transfected cells compared with LVS‑NC‑transfected cells. The results of the western blotting experiments demonstrated that the expression levels of N‑cadherin, vimentin, snail family transcriptional repressor 1 and β‑catenin were notably downregulated, whereas the expression levels of T‑cadherin were markedly upregulated in cell lines stably overexpressing SMARCC2 compared with the LVS‑NC group. In conclusion, the results of the present study suggested that SMARCC2 may inhibit Wnt/β‑catenin signaling by regulating c‑Myc expression in glioma. SMARCC2 regulates the EMT status of the glioblastoma cell line by mediating the expression of the oncogene C‑MYC to inhibit its migration and invasion ability. Thus, SMARCC2 may function as a tumor suppressor or oncogene by regulating associated oncogenes or tumor suppressor genes.

View Figures

View References

1	Wilson BG and Roberts CW: SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer. 11:481–492. 2011. View Article : Google Scholar : PubMed/NCBI
2	He S, Wu Z, Tian Y, Yu Z, Yu J, Wang X, Li J, Liu B and Xu Y: Structure of nucleosome-bound human BAF complex. Science. 367:875–881. 2020. View Article : Google Scholar : PubMed/NCBI
3	Zhou Y, Johnson SL, Gamarra NI and Narlikar GJ: Mechanisms of ATP dependent chromatin remodeling motors. Annu Rev Biophys. 45:153–181. 2016. View Article : Google Scholar : PubMed/NCBI
4	Clapier R, Iwasa J, Cairns BR and Peterson CL: Mechanisms of action and regulation of ATP-dependent chromatin-remodelling complexes. Nat Rev Mol Cell Biol. 18:407–422. 2017. View Article : Google Scholar : PubMed/NCBI
5	Saha A, Wittmeyer J and Cairns BR: Chromatin remodelling: The industrial revolution of DNA around histones. Nat Rev Mol Cell Biol. 7:437–447. 2006. View Article : Google Scholar : PubMed/NCBI
6	Kassabov SR, Zhang B, Persinger J and Bartholomew B: SWI/SNF unwraps, slides, and rewraps the nucleosome. Mol Cell. 11:391–403. 2003. View Article : Google Scholar : PubMed/NCBI
7	Sati S and Cavalli G: Chromosome conformation capture technologies and their impact in understanding genome function. Chromosoma. 126:33–44. 2017. View Article : Google Scholar : PubMed/NCBI
8	Masliah-Planchon J, Bièche I, Guinebretière JM, Bourdeaut F and Delattre O: SWI/SNF chromatin remodeling and human malignancies. Ann Rev Pathol. 10:145–171. 2015. View Article : Google Scholar : PubMed/NCBI
9	Kadoch C, Hargreaves DC, Hodges C, Elias L, Ho L, Ranish J and Crabtree GR: Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet. 45:592–601. 2013. View Article : Google Scholar : PubMed/NCBI
10	Almeida R, Fernández-Justel JM, Santa-María C, Cadoret JC, Cano-Aroca L, Lombraña R, Herranz G, Agresti A and Gómez M: Chromatin conformation regulates the coordination between DNA replication and transcription. Nat Commun. 9:15902018. View Article : Google Scholar : PubMed/NCBI
11	Qiang Z, Jun-Jie L, Hai W, Hong L, Bing-Xi L, Lei C, Wei X, Ya-Wei L, Huang A, Song-Tao Q and Yun-Tao L: TPD52L2 impacts proliferation, invasiveness and apoptosis of glioblastoma cells via modulation of wnt/β-catenin/snail signaling. Carcinogenesis. 39:214–224. 2018. View Article : Google Scholar : PubMed/NCBI
12	Li H, Chen L, Qi S, Yu S, Weng Z, Hu Z, Zhou Q, Xin Z, Shi L, Ma L, et al: HERC3-mediated SMAD7 ubiquitination degradation promotes autophagy-induced EMT and chemoresistance in glioblastoma. Clin Cancer Res. 25:3602–3616. 2019. View Article : Google Scholar : PubMed/NCBI
13	Jackson CM, Choi J and Lim M: Mechanisms of immunotherapy Resistance: Lessons from glioblastoma. Nat Immunol. 20:1100–1109. 2019. View Article : Google Scholar : PubMed/NCBI
14	Tomiyama A and Ichimura K: Signal transduction pathways and resistance to Targeted therapies in glioma. Semin Cancer Biol. 58:118–129. 2019. View Article : Google Scholar : PubMed/NCBI
15	Tan MS, Sandanaraj E, Chong YK, Lim SW, Koh LW, Ng WH, Tan NS, Tan P, Ang BT and Tang C: A STAT3-based gene signature stratifies glioma patients for targeted therapy. Nat Commun. 10:36012019. View Article : Google Scholar : PubMed/NCBI
16	Huang K, Liu X, Li Y, Wang Q, Zhou J, Wang Y, Dong F, Yang C, Sun Z, Fang C, et al: Genome-Wide CRISPR-Cas9 screening identifies NF-κB/E2F6 responsible for EGFRvIII-associated temozolomide resistance in glioblastoma. Adv Sci (Weinh). 6:19007822019. View Article : Google Scholar : PubMed/NCBI
17	Annibali D, Whitfield JR, Favuzzi E, Jauset T, Serrano E, Cuartas I, Redondo-Campos S, Folch G, Gonzàlez-Juncà A, Sodir NM, et al: Myc inhibition is effective against glioma and reveals a role for Myc in profificient mitosis. Nat Commun. 5:46322014. View Article : Google Scholar : PubMed/NCBI
18	Sang Y, Li Y, Zhang Y, Alvarez AA, Yu B, Zhang W, Hu B, Cheng SY and Feng H: CDK5-dependent phosphorylation and nuclear Translocation of TRIM59 promotes macroH2A1 ubiquitination and tumorigenicity. Nat Commun. 10:40132019. View Article : Google Scholar : PubMed/NCBI
19	Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM, Nishikawa R, Rosenthal M, Wen PY, Stupp R and Reifenberger G: Glioma. Nat Rev Dis Primers. 1:150172015. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Method. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Yang M, Wang X, Jia J, Gao H, Chen P, Sha X and Wu S: Tumor protein D52-like 2 contributes to proliferation of breast cancer cells. Cancer Biother Radiopharm. 30:1–7. 2014. View Article : Google Scholar : PubMed/NCBI
22	Zhang J, Cai H, Sun L, Zhan P, Chen M, Zhang F, Ran Y and Wan J: LGR5, a novel functional glioma stem cell marker, promotes EMT by activating the Wnt/β-catenin pathway and predicts poor survival of glioma patients. J Exp Clin Cancer Res. 37:2252018. View Article : Google Scholar : PubMed/NCBI
23	Savas S and Skardasi G: The SWI/SNF complex subunit genes: Their functions, variations, and links to risk and survival outcomes in human cancers. Crit Rev Oncol Hematol. 123:114–131. 2018. View Article : Google Scholar : PubMed/NCBI
24	Bögershausen N and Wollnik B: Mutational landscapes and phenotypic spectrum of SWI/SNF-related intellectual disability disorders. Front Mol Neurosci. 11:2522018. View Article : Google Scholar
25	Alver BH, Kim KH, Lu P, Wang X, Manchester HE, Wang W, Haswell JR, Park PJ and Roberts CW: The SWI/SNF chromatin remodelling complex is required for maintenance of lineage specific enhancers. Nat Commun. 8:146482017. View Article : Google Scholar : PubMed/NCBI
26	Pillidge Z an Bray SJ, . SWI/SNF chromatin remodeling controls Notch-responsive enhancer accessibility. EMBO Rep. 20:e469442019.PubMed/NCBI
27	Wang W, Friedland SC, Guo B, O'Dell MR, Alexander WB, Whitney-Miller CL, Agostini-Vulaj D, Huber AR, Myers JR, Ashton JM, et al: ARID1A, a SWI/SNF subunit, is critical to acinar cell homeostasis and regeneration and is a barrier to transformation and epithelial-mesenchymal transition in the pancreas. Gut. 68:1245–1258. 2019. View Article : Google Scholar : PubMed/NCBI
28	Wang X, Lee RS, Alver BH, Haswell JR, Wang S, Mieczkowski J, Drier Y, Gillespie SM, Archer TC, Wu JN, et al: SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation. Nat Genet. 49:289–295. 2017. View Article : Google Scholar : PubMed/NCBI
29	Nagarajan S, Rao SV, Sutton J, Cheeseman D, Dunn S, Papachristou EK, Prada JG, Couturier DL, Kumar S, Kishore K, et al: ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response. Nat Genet. 52:187–197. 2020. View Article : Google Scholar : PubMed/NCBI
30	Helming KC, Wang X, Wilson BG, Vazquez F, Haswell JR, Manchester HE, Kim Y, Kryukov GV, Ghandi M, Aguirre AJ, et al: ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat. Med. 20:251–254. 2014.PubMed/NCBI
31	Chang L, Azzolin L, Di Biagio D, Zanconato F, Battilana G, Lucon Xiccato R, Aragona M, Giulitti S, Panciera T, Gandin A, et al: The SWI/SNF complex is a mechanoregulated inhibitor of YAP and TAZ. Nature. 563:265–269. 2018. View Article : Google Scholar : PubMed/NCBI
32	Ruijtenberg S and van den Heuvel S: G1/S inhibitors and the SWI/SNF complex control cell-cycle exit during muscle differentiation. Cell. 162:300–313. 2015. View Article : Google Scholar : PubMed/NCBI
33	Wang Q, Zhou Y, Rychahou P, Harris JW, Zaytseva YY, Liu J, Wang C, Weiss HL, Liu C, Lee EY and Evers BM: Deptor is a novel target of Wnt/β-Catenin/c-Myc and contributes to colorectal cancer cell growth. Cancer Res. 78:3163–3175. 2018. View Article : Google Scholar : PubMed/NCBI
34	Lissanu Deribe Y, Sun Y, Terranova C, Khan F, Martinez-Ledesma J, Gay J, Gao G, Mullinax RA, Khor T, Feng N, et al: Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer. Nat Med. 24:1047–1057. 2018. View Article : Google Scholar : PubMed/NCBI
35	Tsurusaki Y, Okamoto N, Ohashi H, Kosho T, Imai Y, Hibi-Ko Y, Kaname T, Naritomi K, Kawame H, Wakui K, et al: Mutations affecting components of the SWI/SNF complex cause Coffin-Siris syndrome. Nat Genet. 44:376–378. 2012. View Article : Google Scholar : PubMed/NCBI
36	Kim KH, Kim W, Howard TP, Vazquez F, Tsherniak A, Wu JN, Wang W, Haswell JR, Walensky LD, Hahn WC, et al: SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat Med. 21:1491–1496. 2015. View Article : Google Scholar : PubMed/NCBI
37	Rogers HA, Sousa S, Salto C, Arenas E, Coyle B and Grundy RG: WNT/β-catenin pathway activation in Myc immortalised cerebellar progenitor cells inhibits neuronal differentiation and generates tumours resembling medulloblastoma. Br J Cancer. 107:1144–1452. 2012. View Article : Google Scholar : PubMed/NCBI
38	Patel R, Brzezinska EA, Repiscak P, Ahmad I, Mui E, Gao M, Blomme A, Harle V, Tan EH, Malviya G, et al: Activation of β-catenin cooperates with loss of pten to drive ar-independent castration-resistant prostate cancer. Cancer Res. 80:576–590. 2020. View Article : Google Scholar : PubMed/NCBI
39	Yu J, Wu SW and Wu WP: A tumor-suppressive microRNA, miRNA-485-5p, inhibits glioma cell proliferation and invasion by down-regulating TPD52L2. Am J Transl Res. 9:3336–3344. 2017.PubMed/NCBI
40	Chen Q, Wang P, Fu Y, Liu X, Xu W, Wei J, Gao W, Jiang K, Wu J and Miao Y: MicroRNA-217 inhibits cell proliferation, invasion and migration by targeting Tpd52l2 in human pancreatic adenocarcinoma. Oncol Rep. 38:3567–3573. 2017.PubMed/NCBI
41	Xu J, Wang W, Zhu Z, Wei Z, Yang D and Cai Q: Tumor protein D52-like 2 accelerates gastric cancer cell proliferation in vitro. Cancer Biother Radiopharm. 30:111–116. 2015. View Article : Google Scholar : PubMed/NCBI
42	Zhou J, Lin Y, Shi H, Huo K and Li Y: hABCF3, a TPD52L2 interacting partner, enhances the proliferation of human liver cancer cell lines in vitro. Mol Biol Rep. 40:5759–5767. 2013. View Article : Google Scholar : PubMed/NCBI